Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells

Cancer Research

Volumn 66, Issue 22, 2006, Pages 11013-11020

  Kalinkovich, Alexander ^a   Tavor, Sigal ^a,c   Avigdor, Abraham ^a,d   Kahn, Joy ^a   Brill, Alexander ^e   Petit, Isabelle ^a   Goichberg, Polina ^a   Tesio, Melania ^a   Netzer, Neta ^a   Naparstek, Elizabeth ^c   Hardan, Izhar ^d   Nagler, Arnon ^d   Resnick, Igor ^e   Tsimanis, Alexander ^b   Lapidot, Tsvee ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBRINOGEN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHEMOKINES, CXC; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, CXCR4; U937 CELLS;

EID: 33845291515     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2006     Document Type: Article

References (47)

1. Juarez J, Bendall L, Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des 2004;10:1245-59.
2. Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004;35:233-45.
3. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005;106:1901-10.
4. Sloane AJ, Raso V, Dimitrov DS, et al. Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1α responses. Immunol Cell Biol 2005;83:129-43.
5. + progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004;103:2942-9.
6. Juarez J, Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 2004;19:299-309.
7. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004;14:181-5.
8. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004;98-117.
9. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998;91:4523-30.
10. Voermans C, van Heese WP, de Jong I, Gerritsen WR, van Der School CE. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 2002;16:650-7.
11. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64:2817-24.
12. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107:1761-7.
13. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004;104:550-7.
14. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2006.
15. Monaco G, Konopleva M, Munsell M, et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004;22:188-201.
16. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006;107:1166-73.
17. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005;20:22-7.
18. Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004;53:210-30.
19. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006;20:1-26.
20. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006;8:79-88.
21. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-95.
22. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005;113:752-60.
23. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006;46:1199-209.
24. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet-and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003;17:33-42.
25. Carnec X, Quan L, Olson WC, Kazan U, Dragic T. Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J Virol 2005;79:1930-3.
26. Valenzuela-Fernandez A, Planchenault T, Baleux F, et al. Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem 2002;277:15677-89.
27. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-94.
28. Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450-9.
29. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005;67:30-8.
30. Spiegel A, Kollet O, Peled A, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004;103:2900-7.
31. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983;79:546-52.
32. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997;99:2118-27.
33. Dahlke MH, Larsen SR, Rasko JE, Schlitt HJ. The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma 2004;45:229-36.
34. De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005;48:1297-313.
35. De La Luz Sierra M, Yang F, Narazaki M, et al. Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity. Blood 2004;103:2452-9.
36. Dar A, Goichberg P, Shinder V, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol 2005;6:1038-46.
37. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503-8.
38. Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-2.
39. Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-12.
40. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003;100:13513-8.
41. Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 2005;9:1267-82.
42. Tavor S, Petit I, Porozov S, et al. Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood 2005;106:2120-7.
43. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002;117:835-41.
44. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-73.
45. Menu E, Asosingh K, Indraccolo S, et al. The involvement of stromal derived factor 1α in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006;91:605-12.
46. Palladino P, Pedone C, Ragone R, Rossi F, Saviano M, Benedetti E. A simplified model of the binding interaction between stromal cell-derived factor-1 chemokine and CXC chemokine receptor 4. Protein Pept Lett 2003;10:133-8.
47. Zaitseva M, Peden K, Golding H. HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta 2003;1614:51-61.